To the Editor:
Thank you for allowing me to comment on the above letter by Dr. Boysen and colleagues. The question 'how much aspirin?' has con cerned neurologists and others ever since its anti-platelet effects were discovered in the late 1960's. It is not, therefore, a new question which has only appeared in response to the more recent discovery of the prostacyclin pathway of prostaglandin metabolism in the vessel wall and its possible protective role against thrombosis.
Reconciling the balance between the 'good' prostaglandins in the vessel wall and the 'bad' prostaglandins in the platelet, and the fact that aspirin inhibits the production of both is a matter which has generated much debate. It seems to me, however, that pharmacologists, on the basis of experiments in animals or in normal human volunteers, can only tell us the best guess at the dose of aspirin to be used in middle aged and elderly individuals with cerebrovascular, or indeed cardiovascular, dis ease. This guess at the dose which will inhibit maximally the 'bad' prostaglandins, but inhibit minimally the 'good' prostaglandins, must then be validated by clinical trials. The Canadian Trial in threatened stroke patients, and practically all the other major trials of aspirin, used a dose of about 1 gram daily because that was the best guess in the early 1970's when these trials were designed. Whether this dose of aspirin really does increase the survival period free of stroke after TIA has been vigorously debated and in response to this debate, and in response to the dose issue, the UK-TIA Aspirin Trial was initiated in 1978 and the first patient randomized in August 1979. In this trial TIA patients are ran domised three ways, and the males and females are being analysed separately or together. Aspirin 600 mgs. b.d. is being compared to placebo to investigate whether the result of the Canadian Trial is correct and, in a third treatment arm, aspirin 300 mgs. daily is being used since, back in 1978, this was the best guess at the most effective antithrombotic dose regime. To date just over 1200 patients have been randomised and the aim is to recruit about 2000 by the end of 1983. So far 92 end points have occurred (stroke, myocardial infarction, death) and the stopping rules have not yet had to be invoked. Only 2 patients have been lost to follow-up although many are no longer taking their trial medication.
From the results of this trial it should be possible to answer the question whether 1200 mgs. or 300 mgs. of aspirin daily has a clinically useful affect on the risk of stroke, myocardial infarction, and death after TIA. If therer is little to choose in therapeutic effectiveness between the two doses it would be an advantage to use the lower one since it is cheaper, and almost certainly associated with fewer gastrointestinal side effects. Obviously one concern is that 300 mgs/ daily will still be 'too much' and that neither dose of aspirin will have a clinically useful effect. However, it is only by doing trials such as this that the best dose will emerge and, importantly, become believable in real clinical practice. Naturally we look to our pharmacological colleagues to provide some idea of the best dose and hope that the number of their guesses will not be excessive -for each guess at the dose of aspirin, or indeed any other antithrombotic drug, many hundreds of TIA patients need to be ran domised to have a reasonable degree of certainty of turning a guess into clinical reality. To the Editor: I agree that the doses used in the two stroke studies cited (reference 4 and 5) were greater than the minimum amount required to inhibit plate let prostaglandins synthesis. It cannot be assumed, however, that the antithrombotic effect of aspirin is limited to this single action of the drug. Thus, in the study by McKenna and associates, very large doses of aspirin were found to be more effective than moderate doses of aspirin in preventing venous thrombosis after knee surgery and there is experi mental evidence that very high doses of aspirin have additional effects on platelet function. It is known that salicylate inhibits the platelet lipoxygenase pathway which may also be important in platelet aggrega tion. For these reasons, it is inappropriate to conclude that doses of ASA used in the studies cited (although unconvincing to Boysen and associ ates) were excessive.
I agree, however, that it would be highly appropriate to do further studies using smaller doses of ASA to determine whether these are more To the Editor: In a recent paper describing interesting experiments to measure the plasma and red cell transit in a cerebral ischemic area of the cat brain (Stroke 12: 218-223, March-April, 1981), Little et al. reported that the transit time of plasma as represented by 131 I albumin was shorter than that of red cells labeled with "Tc even in the control State. This is just the opposite of data reported by us 1 in the cat brain using our photoelectric method. It also contrasts with the results of other groups including Larsen & Lassin in the brain, 2 Pappenheimer & Kinter in the kidney, 3 Rapaport et al. in the lung, 4 Moore & Baker in the skeletal muscle, 5 and Freis et al. through the forearm. 6 All these authors found that the velocity of red cells exceeded that of plasma. These findings were supported by the larger plasma volume than red cell volume in the tissue. rHct. 100 x t rc /t p In other words, the ratio of the mean transit time for red cells and that for the plasma is approximately the tissue hematocrit relative to that of the large vessels.
The data of Little et al. would imply therefore that the cerebral tissue hematocrit is higher than the large vessel hematocrit, which is incredi ble. A closer examination of their analytical method shows that the transit time was determined by them from measurements of the total peak time. We believe that the tissue concentration curve which they recorded was a cumulative distribution function, whose peak time rep resented only the arterial phase, and by no means the microcirculatory phase as they claimed. Even with any contribution from the arterial phase, their data are dubious due to the existence of the FahraeusLindqvist effect. We recommend that they recheck their data pertinent to the above criticism. 
